Search - tctmd.com

Displaying 281 - 300 of 347

Sort: Relevancy | Date

News Conference News EuroPCR 2017

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Michael O'Riordan

May 17, 2017

REPRISE III: Lotus Valve Matches CoreValve in First Head-to-Head TAVR Trial

News Conference News EuroPCR 2017

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

Shelley Wood

May 16, 2017

News Industry News

The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global REPRISE III Trial at One Year

May 15, 2017

News Daily News

Balloon Predilation Not Mandatory Before TAVR, Meta-analysis Suggests

Caitlin E. Cox

April 21, 2017

News Daily News

Permanent Pacemakers After TAVR: Model Helps Predict Individual Patient Risk With Sapien 3

L.A. McKeown

April 12, 2017

News Conference News ACC 2017

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

Shelley Wood

March 24, 2017

News Daily News

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Todd Neale

March 22, 2017

News Conference News ACC 2017

Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients

L.A. McKeown

March 21, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

Presentation SIF 2017

Best Practices: Evolut R

Presenter: Ramon Quesada

March 11, 2017

News Conference News CRT 2017

Amid Sluggish Trial Enrollment, Transcatheter Mitral Valve Field Asks: Just How Big Is the Unmet Need?

Michael O'Riordan

February 27, 2017

News Conference News CRT 2017

Lotus TAVR Device With Depth Guard Reduces Risk of Pacemaker Implantation

Michael O'Riordan

February 22, 2017

Presentation JIM 2017

CoreValve™ Evolut™ R Tavi System Intermediate Risk Indication

Presenter: Alberto Cremonesi

February 10, 2017

News Daily News

Early Clinical Outcomes With Evolut R Reassure, Suggest Improvements Over First-Gen CoreValve

Michael O'Riordan

February 09, 2017

Presentation

Initial Experience of Second-Generation Self-Expandable TAVR System (Evolut R)

February 09, 2017

Presentation

Early Clinical Outcomes with Self-Expandable TAVR System (Evolut R) in Severe AS

Presenter: Jeffrey Popma

February 09, 2017

News Daily News

Clinical Outcomes With Subclavian TAVR as Good as With Transfemoral Access, Small Analysis Shows

Michael O'Riordan

January 26, 2017

News Features

The Prickly Problem of Permanent Pacing After TAVR: One Hospital Pitches a Protocol

Michael O'Riordan

January 24, 2017

Advertisement

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global REPRISE III Trial at One Year

Balloon Predilation Not Mandatory Before TAVR, Meta-analysis Suggests

Permanent Pacemakers After TAVR: Model Helps Predict Individual Patient Risk With Sapien 3

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

FDA Approves Next-Gen CoreValve Evolut PRO Valve

Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Live From Washington: ACC 2017, Day One

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Best Practices: Evolut R

Amid Sluggish Trial Enrollment, Transcatheter Mitral Valve Field Asks: Just How Big Is the Unmet Need?

Lotus TAVR Device With Depth Guard Reduces Risk of Pacemaker Implantation

CoreValve™ Evolut™ R Tavi System Intermediate Risk Indication

Early Clinical Outcomes With Evolut R Reassure, Suggest Improvements Over First-Gen CoreValve

Initial Experience of Second-Generation Self-Expandable TAVR System (Evolut R)

Early Clinical Outcomes with Self-Expandable TAVR System (Evolut R) in Severe AS

Clinical Outcomes With Subclavian TAVR as Good as With Transfemoral Access, Small Analysis Shows

The Prickly Problem of Permanent Pacing After TAVR: One Hospital Pitches a Protocol

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content